Bank Of New York Mellon Corp Aprea Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

$541 Trillion
Q4 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.62 - $1.94 $37 - $116	-60 Reduced 0.36%	16,643 $12,000
Q1 2022 May 11, 2022	SELL	$1.59 - $3.16 $222 - $442	-140 Reduced 0.83%	16,703 $31,000
Q2 2021 Aug 11, 2021	SELL	$4.05 - $5.5 $125,307 - $170,170	-30,940 Reduced 64.75%	16,843 $82,000
Q1 2021 May 13, 2021	BUY	$4.73 - $8.15 $82,524 - $142,193	17,447 Added 57.51%	47,783 $243,000
Q4 2020 Feb 09, 2021	BUY	$4.92 - $30.67 $8,979 - $55,972	1,825 Added 6.4%	30,336 $149,000
Q3 2020 Nov 12, 2020	BUY	$21.66 - $38.86 $44,056 - $79,041	2,034 Added 7.68%	28,511 $685,000
Q2 2020 Aug 12, 2020	SELL	$25.47 - $39.69 $292,293 - $455,482	-11,476 Reduced 30.24%	26,477 $1.03 Million
Q1 2020 May 06, 2020	BUY	$31.65 - $45.3 $676,866 - $968,785	21,386 Added 129.09%	37,953 $1.32 Million
Q4 2019 Feb 14, 2020	BUY	$18.94 - $49.53 $313,778 - $820,563	16,567 New	16,567 $760,000

Others Institutions Holding APRE

# of Institutions

1

Shares Held

0

Call Options Held

0

Put Options Held

0

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.